| 32nd week of 2013 patent applcation highlights part 37 |
| Patent application number | Title | Published |
|---|
| 20130202523 | PROCESS FOR PREPARATION OF ZEOLITIC MATERIAL - The present invention relates to a process for process for the preparation of a zeolitic material which process comprises (i) providing a boron-containing zeolitic material and (ii) deboronating the boron-containing zeolitic material by treating the boron-containing zeolitic material with a liquid solvent system thereby obtaining a deboronated zeolitic material, which liquid solvent system does not contain an inorganic or organic acid, or a salt thereof. | 2013-08-08 |
| 20130202524 | Iron- And Copper-Containing Zeolite Beta From Organotemplate-Free Synthesis And Use Thereof In The Selective Catalytic Reduction Of NOx - Provided is a process for the production of a zeolitic material having a BEA-type framework structure comprising YO | 2013-08-08 |
| 20130202525 | MULTIFUNCTIONAL NANOPLATFORMS FOR FLUORESCENCE IMAGING AND PHOTODYNAMIC THERAPY DEVELOPED BY POST-LOADING PHOTOSENSITIZER AND FLUOROPHORE TO POLYACRYLAMIDE NANOPARTICLES - A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and a postloaded imaging agent and methods for making and using same. | 2013-08-08 |
| 20130202526 | PAA NANOPARTICLES FOR PET IMAGING AND PDT TREATMENT - PAA nanoparticles containing at least one tetrapyrrolic photosensitizer and at least one PET imaging agent. | 2013-08-08 |
| 20130202527 | Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain And Mucin Domain 1 (TIM-1) Antigen - The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided. | 2013-08-08 |
| 20130202528 | DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS - Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137 (4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptpm (IA-2), CD109, Ankylosis, and collagen VIIIα1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed. | 2013-08-08 |
| 20130202529 | BENZTROPINE COMPOUNDS AND USES THEREOF - Disclosed are benztropine analogs having the formula (I) | 2013-08-08 |
| 20130202530 | NOVEL RADIOTRACER - Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal, ovarian, endometrial, lung and prostate cancer—primary tumor, nodal disease or metastases). The present invention also describes intermediate(s), pre-cursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s). | 2013-08-08 |
| 20130202531 | INDICATORS FOR DETECTING THE PRESENCE OF METABOLIC BYPRODUCTS FROM MICROORGANISMS - Polymeric indicator films and pH indicating wraps are provided for visually monitoring, detecting, and/or determining the presence of metabolic byproducts from harmful or potentially harmful microorganisms. Also provided are methods of use and preparation of the polymeric indicator films. | 2013-08-08 |
| 20130202532 | MULTIPLE INPUT BIOLOGIC CLASSIFIER CIRCUITS FOR CELLS - Provided herein are high-input detector modules and multi-input biological classifier circuits and systems that integrate sophisticated sensing, information processing, and actuation in living cells and permit new directions in basic biology, biotechnology and medicine. The multi-input biological classifier circuits described herein comprise synthetic, scaleable transcriptional/post-transcriptional regulatory circuits that are designed to interrogate the status of a cell by simultaneously sensing expression levels of multiple endogenous inputs, such as microRNAs. The classifier circuits then compute whether to trigger a desired output or response if the expression levels match a pre-determined profile of interest. | 2013-08-08 |
| 20130202533 | METHODS FOR MODULATING SKELETAL REMODELING AND PATTERNING BY MODULATING SHN2 ACTIVITY, SHN3 ACTIVITY, OR SHN2 AND SHN3 ACTIVITY IN COMBINATION - This invention is based, at least in part, on the discovery that Shn2 and Shn3 play an important role in skeletal remodeling and skeletal patterning. Accordingly, the present invention provides methods for identifying medulators of Shn2 activity and methods for modulating bone formation and mineralization and Shn2-associated disorders using agents that modulate Shn2 expression and/or activity, in addition to methods for modulating Shn2 and Shn3. | 2013-08-08 |
| 20130202535 | X-RAY VISIBLE MEDICAL DEVICE AND PREPARATION METHOD THEREOF - The present invention relates to an X-ray visible medical device comprising a medical device and a layer bound onto the medical device, wherein the layer is composed of an X-ray contrast material or a composite of the X-ray contrast material and a biocompatible polymer. Also disclosed is a method for preparing the X-ray visible medical device. | 2013-08-08 |
| 20130202536 | FLUOROPHORE CHELATED LANTHANIDE LUMINESCENT PROBES WITH IMPROVED QUANTUM EFFICIENCY - The invention relates to novel luminescent compositions of matter containing a fluorophore, synthetic methods for making the compositions, macromolecular conjugates of the compositions, and the use of the compositions in various methods of detection. The invention also provides kits containing the compositions and their conjugates for use in the methods of detection. | 2013-08-08 |
| 20130202537 | COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE - The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or nerves and for compositions thereof. | 2013-08-08 |
| 20130202538 | Molecular Switch - Photosensitive molecular switch, having a chelate ligand, a metal ion bonded coordinatively to the chelate ligand, the metal ion being selected from the group of metal ions consisting of Mn | 2013-08-08 |
| 20130202539 | ORAL CARE COMPOSITIONS - The invention provides an oral care composition obtainable by: (i) preparing an oil-in-water emulsion by dispersing an oil phase into an aqueous continuous phase, the aqueous continuous phase comprising an oil-in-water emulsifier which is selected from one or more hydrophobins, so that emulsified particles of oil phase are formed which are emulsified with the one or more hydrophobins; and (ii) combining the emulsion so obtained with an oral care base formulation which is suitable for treating the surfaces of the oral cavity. Compositions of the invention demonstrate enhanced deposition of oil phase components onto oral cavity surfaces such as tooth enamel and tooth dentine, and in particular onto damaged surfaces such as scratched and demineralised enamel. | 2013-08-08 |
| 20130202540 | METHOD FOR REPAIR OF ACUTE AND CHRONIC INJURY, SUCH AS BURNED AND PHOTODAMAGED SKIN - A chemical compound and a method for its use as a topical medication that can reverse the effects of sun-damage, reverse the signs of aging, demonstrate anti-scarring properties and allow for the treatment of acne while still permitting the patient the ability to simultaneously expose the affected area to the sun without damage that includes a combination of curcumin, alcohol, carbomer, diazolidinylurea, additional penetration enhancer—such as alliin, additional agent capable of blocking both UVA and UVB such as pearl powder, anti-inflammatory agent such as aloe vera, water, glycerin and preservative as needed, and an acidifying agent to product the correct pH. Allinin is used as an s-allyl side chain to increase the penetration of curcumin into the cells. Pearl powder is used to block the effects harmful UVA and UVB. | 2013-08-08 |
| 20130202541 | COMPOSITION CONTAINING EXTRACT OF VENUS FLYTRAP FOR COSMETIC TREATMENT - The present invention relates to an extract of | 2013-08-08 |
| 20130202542 | USE OF SILANE AND SILOXANE BIS(BIPHENYL) TRIAZINE DERIVATIVES AS UV ABSORBERS - Disclosed is the use of silane and siloxane bis(biphenyl)triazine derivatives of formula (1), wherein n is a number from 1 to 4; if n=1, X is *-L-Sil; or a radical of formula (11′), L is a linker selected from a radical of formula (2); R | 2013-08-08 |
| 20130202543 | USE OF POLYOLS FOR ENHANCING THE COOLING EFFECT OF A COOLING SUBSTANCE AND COOLING MIXTURES HAVING AN ENHANCED COOLING EFFECT - The invention relates to a use of one, two, three or more certain polyols for enhancing the cooling effect of a cooling substance. It further relates to a cooling mixture comprising a cooling effect enhancing polyol and a cooling substance consisting of one or more physiologically cooling compounds and optionally further compounds having a further enhancing effect on the cooling effect of the substance, too. Moreover the invention relates to a method for producing a corresponding cooling mixture and a method for generating an enhanced cooling effect of a cooling substance on the skin or a mucous membrane. | 2013-08-08 |
| 20130202544 | THICKENED COMPOSITONS OF HIGH PH - Provided herein are thickened compositions produced upon assembling a first sub-formulation having a hydroxide, and at least one second sub -formulation having an alkaline material, wherein at least one sub-formulation is thickened by lightly-to moderately-crosslinked PVP. Unlike other compositions not having the lightly-to moderately-crosslinked PVP, those described herein maintain or even build viscosity when the first and second sub -formulations are blended. The compositions may be utilized in the formulation of personal care and performance chemicals, such as hair relaxers, hair straighteners, depilators, degreasers, paint strippers, and cleaners. Methods for enhancing product handling and performance are also described. | 2013-08-08 |
| 20130202545 | Stablised Polyphenol Derivatives, Process for Their Manufacture, and Uses Thereof - The present invention relates to derivatized polyphenols, wherein all of the reactive phenolic hydroxyl functional groups are completely esterified or etherified, as demonstrated by the absence of free hydroxyl groups in an infrared absorption spectrum of the derivatized product. Due to their increased stability, the derivatized polyphenols can be used in cosmetic and pharmaceutical formulations more effectively, targeting and releasing active anti-oxidant polyphenols via natural biological degradative mechanisms in situ in the targeted areas. | 2013-08-08 |
| 20130202546 | Cosmetic Compositions Having Persistent Tightening Effects - Cosmetic compositions are provided, which are capable of having a tightening and/or curling effect on a human integument when applied thereto. Cosmetic compositions according to the invention typically include a cosmetically acceptable vehicle and a pH-dependent film-forming polymer of either a poly(methacrylic acid-co-methyl methacrylate) or a poly(methacrylic acid-co-ethyl acrylate). The tightening and/or curling effect of these cosmetic compositions is prolonged and substantially resistant to environmental stresses such as increased heat or humidity. | 2013-08-08 |
| 20130202547 | Ophthalmic Compositions Containing Diglycine - Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 0.01 ppm to 3 ppm poly(hexamethylene biguanide); 1 ppm to 10 ppm α-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl)ammonium chloride; and 0.1% w/v to 2% w/v of one or more boron buffering compounds. | 2013-08-08 |
| 20130202548 | IMMUNOMODULATORY PROTEIN CONSTRUCTS WITH A HELICAL POLYMERIC BACKBONE - The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example, for immunotherapy, such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and/or diagnostic purposes. | 2013-08-08 |
| 20130202549 | USE OF DPAS AND CO-POLYMERS FOR HYPERLIPIDEMIA AND ATHEROSCLEROSIS ALONG WITH REDUCING FEEDING RATE AND ADIPOSE TISSUE WEIGHT OF OBESITY ANIMAL - The disubstituted piperazine analogs (DPAs) derivative compound and DPAs amine complex compound disclosed in the present aspects have characterized by presented pharmaceutics having functions to improve lipolysis, such as inhibiting obesity hyperlipidemia, and atherosclerosis. | 2013-08-08 |
| 20130202550 | NON-ANTICOAGULANT SULFATED OR SULFONATED SYNTHETIC POLYMERS - The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro. | 2013-08-08 |
| 20130202551 | IONIC COMPOUND, COMPOSITION, CURED MATERIAL, HYDROGEL AND OPHTHALMIC LENS - An ionic compound capable of providing a cured material having superior antibacterial property and oxygen permeability, and a composition containing the ionic compound, and a cured material, a hydro gel and an ophthalmic lens which have long-term sustainable antibacterial property and superior oxygen permeability. The ionic compound is represented by the following formula (1): | 2013-08-08 |
| 20130202552 | BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS - The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membrane signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence. | 2013-08-08 |
| 20130202553 | MOBILIZATION OF HEMATOPOIETIC STEM CELLS - Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more additional agents. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve specific inhibition of the Cdc42 GTPase to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject. | 2013-08-08 |
| 20130202554 | COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE - Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen. | 2013-08-08 |
| 20130202555 | TREATMENT OF MULTIPLE SCLEROSIS WITH MASITINIB - The present invention relates to a tyrosine kinase inhibitor or a mast cell inhibitor, and in particular masitinib or a pharmaceutically acceptable salt thereof, for the treatment of human multiple sclerosis. | 2013-08-08 |
| 20130202556 | Treatment of Hepatitis C Virus Related Diseases Using Hydroxychloroquine or a Combination of Hydroxychloroquine and an Anti-Viral Agent - Methods of treating a hepatitis C virus (HCV) related disease, such as HCV infections in subjects non-responsive to anti-HCV therapy, are described herein, comprising administering to the subject a therapeutically effective amount of hydroxychloroquine. An antiviral agent may be co-administered with the hydroxychloroquine. Methods utilizing synergistic combinations of hydroxychloroquine and an antiviral agent are disclosed. Further disclosed are compositions comprising hydroxychloroquine and an antiviral agent, as well as hydroxychloroquine and uses thereof for the treatment of a hepatitis C virus (HCV) related disease. | 2013-08-08 |
| 20130202557 | ORAL DELIVERY OF NUCLEIC ACID-BASED GENE INTERFERING AGENTS BY SALMONELLA - The present invention provides vectors, including a novel attenuated strain of | 2013-08-08 |
| 20130202558 | RECOMBINANT REPLICATION COMPETENT ONCOLYTIC VIRUSES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER - Improved NCD variants exhibiting enhanced bioavailability and stability for the treatment of cancer are provided. | 2013-08-08 |
| 20130202559 | Use of Microvesicles in the Treatment of Medical Conditions - This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications. | 2013-08-08 |
| 20130202560 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION AND TREATMENT CONTAINING THE C12ORF59 GENE OR PROTEIN AS AN ACTIVE INGREDIENT - As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over-expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer. | 2013-08-08 |
| 20130202561 | METHOD OF TREATING DRAINS USING FUNGUS CULTURES - A method of treating drain systems containing organic matter and providing a biopesticide for killing insects is provided. The method comprises introducing into a drain system a bacterial culture, such as | 2013-08-08 |
| 20130202562 | LIQUID MICROORGANISM CONSORTIA FORMULATION - The present invention is directed to compositions and methods using microorganisms to benefit an environment or recipient subject. The present invention relates to the use of microorganism based compositions and methods to enhance the health of recipient subjects, improve soil conditions, and accelerate biodegradation. The present invention also relates to controlling insect and pest populations. Further, the present invention relates to the replacement of chemical compositions with microorganism based compositions. | 2013-08-08 |
| 20130202563 | DECELLULARIZED ADIPOSE CELL GROWTH SCAFFOLD - Provided herein are methods of making a cell growth scaffold from adipose tissue, cell growth scaffolds having low lipid content and methods of using the cell growth scaffold. | 2013-08-08 |
| 20130202564 | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration - This invention provides a composition for controlled-release of polypeptide growth factors useful in tissue repair or engineering. The composition include a polypeptide growth factor covalently cross-linked to a biocompatible substrate by a transgultaminase. The cross-linking tethers the growth factor to a substrate so that it will not diffuse away from the desired site of application. It also concomitantly inactivates the growth factor. Release and reactivation of the growth factor can be achieved by endogenously produced metalloproteinase (MMPs) or exogenously provided proteases such as collagenases. Also provided are scaffolds, transplant devices, methods for using the same and methods for making the same, | 2013-08-08 |
| 20130202565 | METHOD FOR INDUCING DIFFERENTIATION OF ADULT STEM CELLS AND NERVE CELLS USING ELECTROMAGNETIC FIELD - The present invention relates to a method for differentiation of mesenchymal stem cells or dental pulp stem cells. More specifically, the invention relates to a method for differentiating stem cells to neural cells by applying mesenchymal stem cells or dental pulp stem cells with a low-frequency electromagnetic field. The differentiation method according to the present invention can induce differentiation even with low-cost mediums rather than induced neural differentiation mediums which are expensive due to addition of growth factors, and the neural cells differentiated according to the present invention may be useful for treatment of neurological brain diseases. | 2013-08-08 |
| 20130202566 | METHOD FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS TO NERVE CELLS USING SOUND WAVES - The present invention relates to a method for differentiation of mesenchymal stem cells. More specifically, the invention relates to a method for differentiating mesenchymal stem cells to neural cells by treating the mesenchymal stem cells with low-frequency sound waves. The differentiation method of the present invention can induce differentiation even with low-cost media rather than induced neural differentiation mediums which are expensive due to addition of growth factors, and the neural cells differentiated according to the present invention may be useful for treatment of neurological diseases. | 2013-08-08 |
| 20130202567 | TISSUE CULTURE MEDIA CONTAINING TRIMETHYLAMINE N-OXIDE - The present disclosure provides cell culture medium comprising trimethylamine N-oxide (TMAO). Progenitor cells cultured with such medium can form connective tissue with enhanced mechanical properties. Also provided are methods of forming connective tissue and methods of treatment for connective tissue defects. | 2013-08-08 |
| 20130202568 | Ameliorating Nervous Systems Disorders - The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition. | 2013-08-08 |
| 20130202569 | Transgenic Ungulates Expressing CTLA4-IG and Uses Thereof - The present invention provides ungulates, including pigs, expressing CTLA4-Ig, as well as tissue, organs, cells and cell lines derived from such animals. Such animals, tissues, organs and cells can be used in research and medical therapy, including xenotransplanation. In addition, methods are provided to prepare organs, tissues and cells expressing the CTLA4-Ig for use in xenotransplantation, and nucleic acid constructs and vectors useful therein. | 2013-08-08 |
| 20130202570 | Treatment of Neurocutaneous Syndrome, Including Compositions, Methods and Uses Thereof - A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof. | 2013-08-08 |
| 20130202571 | USE OF PROBIOTIC BACTERIA TO PREVENT AND TREAT LISTERIAL INFECTIONS - This invention relates to LAP-expressing probiotic bacteria and methods of use thereof to prevent and treat a pathogenic bacterial infection. | 2013-08-08 |
| 20130202572 | CAFFEINE-FREE DIETARY SUPPLEMENTS FOR INCREASING ENERGY AND METHODS OF ADMINISTERING THE SAME - Disclosed herein are caffeine-free dietary supplements for increasing energy in a subject and methods of administering the same. The method comprises administering to a subject a caffeine-free dietary supplement comprising omega-3 fatty acids, resveratrol, beta-alanine, gamma aminobutyric acid, and valerian root extract product, in amounts such that the supplement is effective for increasing energy and mental focus and relieving stress in the subject. | 2013-08-08 |
| 20130202573 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 2013-08-08 |
| 20130202574 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF VALYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-08-08 |
| 20130202575 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-BETA-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-08-08 |
| 20130202576 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF HISTIDYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-08-08 |
| 20130202577 | DIAGNOSTIC AND PROGNOSTIC ASSAY FOR BREAST CANCER - The invention relates to the finding that T cell protein tyrosine phosphatase (TCPTP) has a tumour suppressor function. In one particular application, the invention provides a method of diagnosis and/or prognosis of cancer in a subject involving the assessment, in a suitable body sample, of any lack or reduction of TCPTP protein and/or Ptpn2 gene expression. The invention also provides a method of treating or preventing cancer in a subject involving administering to a subject an agent for modulating the activity of TCPTP. | 2013-08-08 |
| 20130202578 | COMPOSITIONS AND METHODS FOR SELECTIVELY PRODUCING SIRNA - The disclosure provided herein provides compositions and methods for producing siRNA. Also disclosed are compositions and methods for modulating the production of siRNA. Also disclosed herein are compositions and methods of treating a disease in a subject comprising administering a Dicer enzyme comprising a helicase domain or a mutated Dicer enzyme to a subject. Also disclosed herein are methods of screening for a candidate modulator that modulates siRNA production. | 2013-08-08 |
| 20130202579 | USE OF CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE-ALPHA (CCT-ALPHA) AS A BIOMARKER FOR CANCER PROGNOSIS - It has previously been demonstrated that positive 8F1 immunohistochemistry is an indicator of a poor cancer prognosis and poor response to chemotherapy. The 8F1 antibody was generated by immunization against ERCC1, a DNA repair protein, but recognizes a second, previously unidentified protein in cells and tissues. Disclosed herein is the finding that in addition to ERCC1, the 8F1 antibody recognizes the choline phosphate cytidylyltransferase-α (CCTα) protein. Thus, provided herein is a method of determining the prognosis of a patient with cancer by specifically detecting expression of CCTα in a sample obtained from the subject. Also provided is a method of predicting the response of a cancer patient to treatment with a genotoxic therapy by specifically detecting expression of CCTα in a sample obtained from the subject. | 2013-08-08 |
| 20130202580 | Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis - The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis. | 2013-08-08 |
| 20130202581 | ENZYME COMPOSITIONS AND USE THEREOF FOR WOUND HEALING - Compositions and methods of using the compositions for wound healing are provided. The compositions include one or more digestive enzymes, for example, one or more protease, lipases, and amylases. The compositions can be formulated as topical pharmaceutical compositions and can be used for faster healing through stimulation of epidermal cells in the absence of scarring. The compositions may deposit a short term fibrosis and help prevent re-opening of wounds. The compositions may improve recruitment of white blood cells, thereby inducing or enhancing growth factor and immune system activation via an enzyme antibiotic effect. The compositions may enhance the epidermal integrity beyond that of the normal physiological restorative process. Application of the compositions may result in greater re-growth of hair on regions of wounds healed with enzyme and reduced alopecia. The compositions may be administered without causing allergic reactions and without causing biological damage or burns. | 2013-08-08 |
| 20130202582 | AGENT DELIVERY SYSTEM CAPABLE OF SELECTIVELY RELEASING AN AGENT - The present invention provides a composition for selectively delivering an active agent to a portion of an organism. The composition comprises first and second polymer portions, having first and second functional groups attached as a side-chain thereto, respectively. The first and second functional groups form cross-links between the first and second polymer portions. The cross-links are capable of being broken by a substance of the organism, thereby resulting in release of the active agent. The composition provides a novel means for controlling the selective release of the active agent in the organism. | 2013-08-08 |
| 20130202583 | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof - Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided. | 2013-08-08 |
| 20130202584 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 - The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8. | 2013-08-08 |
| 20130202585 | STABILISING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND IN LYOPHILISED FORM - This invention is related to a stabilising formulation for immunoglobulins G compositions comprising a sugar alcohol, glycine and a non-ionic detergent, which is suitable for the stabilisation of immunoglobulins G compositions in liquid form and in lyophilised form. The invention also relates to an immunoglobulins G composition in liquid form or in lyophilised form comprising said stabilising formulation. | 2013-08-08 |
| 20130202586 | STEM CELL THERAPY USING INHIBITORS OF LYSOPHOSPHATIDIC ACID - Methods are provided for stem cell therapy using inhibitors of lysophosphatidic acid (LPA). Inhibition of LPA may be direct or indirect; particularly preferred direct inhibitors of LPA are antibodies to LPA, including humanized monoclonal antibodies to LPA. Such inhibitors are used in combination with stem cells for the treatment of injuries, diseases, or conditions amenable to treatment by stem cell therapy. | 2013-08-08 |
| 20130202587 | IDENTIFICATION OF GENETIC VARIANTS - The present disclosure provides a method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the presence or absence of an allelic variant indicates whether the subject is more or less likely to be responsive to VEGF-based therapy. | 2013-08-08 |
| 20130202588 | Antitumor T Cell Response Enhancer - An objective of the present invention is to provide novel therapeutic agents for cancer, which have an excellent antitumor effect in cancer patients by enhancing their immune function. The present inventors discovered that the administration of at IL-6 inhibitor and/or gemcitabine or a salt thereof to tumor-bearing organisms yields an excellent antitumor T cell response-enhancing effect, and completed the present invention. In addition, the present inventors discovered that the T cell response-enhancing effect produces an excellent antitumor effect. | 2013-08-08 |
| 20130202589 | DIAGNOSIS AND TREATMENT OF AUTOANTIBODY-MEDIATED HEART DISEASE - Provided herein are, inter alia, methods of diagnosing and treating autoimmune cardiomyopathy in subjects, based upon the detection of IgG4 antibodies to cardiac autoantigens. | 2013-08-08 |
| 20130202590 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH A COMBINATION THERAPY USING LENALIDOMIDE AND AZACITIDINE - Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine. | 2013-08-08 |
| 20130202591 | ANTIBODIES DIRECTED AGAINST IL-17 - The disclosure relates to an isolated IL-17-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1 and optionally an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The disclosure also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease. | 2013-08-08 |
| 20130202592 | Composition for the Anti-Cancer Metastasis Containing DLK1-Fc Fusion Protein as an Effective Ingredient - A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis. | 2013-08-08 |
| 20130202593 | INTRACELLULAR IMMUNITY - A compound which may comprise a ligand which binds, directly or indirectly, specifically to an antigen of a pathogen, provided that said ligand is not the PRYSPRY domain of TRIM21; and a RING domain and/or an inducer of TRIM21 expression. | 2013-08-08 |
| 20130202594 | ALK1 Antagonists and Their Uses in Treating Renal Cell Carcinoma - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo. | 2013-08-08 |
| 20130202595 | Factor IX Polypeptides and Methods of Use Thereof - The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 2013-08-08 |
| 20130202596 | Processable Single Chain Molecules and Polypeptides Made Using Same - The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described. | 2013-08-08 |
| 20130202597 | ANTI-SERUM ALBUMIN BINDING VARIANTS - The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts. | 2013-08-08 |
| 20130202598 | ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE INHIBITORY PEPTIDE - The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease. | 2013-08-08 |
| 20130202599 | NOVEL IMMUNOGLOBULINS INSERTIONS, DELETIONS, AND SUBSTITUTIONS - An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide. | 2013-08-08 |
| 20130202600 | Polypeptides And Methods For Modulating D1-D2 Dopamine Receptor Interaction And Function - The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling. | 2013-08-08 |
| 20130202601 | ASSAYS, METHODS AND KITS FOR PREDICTING RENAL DISEASE AND PERSONALIZED TREATMENT STRATEGIES - Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the afore-mentioned disorders. | 2013-08-08 |
| 20130202602 | BIOMARKERS OF IMMUNOMODULATORY EFFECTS IN HUMANS TREATED WITH ANTI-CD200 ANTIBODIES - The present disclosure relates to anti-CD200 antibodies (e.g., variant anti-CD200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce a desired immunomodulatory effect in the human and/or selecting an appropriate dosing schedule for a patient. | 2013-08-08 |
| 20130202603 | BISPECIFIC SINGLE CHAIN Fv ANTIBODY MOLECULES AND METHODS OF USE THEREOF - Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family. | 2013-08-08 |
| 20130202604 | Therapeutic Uses of Monoclonal Antibodies to the Angiotensin-II Type-1 Receptor - The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence | 2013-08-08 |
| 20130202605 | PROTEIN SUSTAINED-RELEASE INJECTABLE FORMULATION - The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof. | 2013-08-08 |
| 20130202606 | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same - The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC. | 2013-08-08 |
| 20130202607 | ANTI-SYSTEM ASC AMINO ACID TRANSPORTER 2 (ASCT2) ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof. | 2013-08-08 |
| 20130202608 | MONOCLONAL ANTIBODY SPECIFIC TO MAJOR NEUTRALIZING EPITOPE OF INFLUENZA H5 HEMAGGLUTININ - The present invention relates to the murine monoclonal antibody 4C2 or to chimeric or humanized monoclonal antibodies specific to a major neutralizing epitope of influenza H5 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using such murine or chimeric or humanized monoclonal antibodies or fragments thereof. | 2013-08-08 |
| 20130202609 | GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES - The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against | 2013-08-08 |
| 20130202610 | METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS - The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody. | 2013-08-08 |
| 20130202611 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2013-08-08 |
| 20130202612 | COMPOSITIONS AND METHODS FOR TREATING BONE CONDITIONS - A method of treating a degenerative bone condition of a subject includes administering to hematopoietic progenitor cells or osteoclast progenitor cells of the subject at least one agent that substantially reduces the interaction of at least one of C3a or C5a with the C3a receptor (C3aR) and/or C5a receptor (C5aR), a STAT3/IL-6 signaling pathway antagonist, and a combination thereof, the agent being administered to the hematopoietic progenitor cells or osteoclast progenitor cells at an amount effective to inhibit osteoclast differentiation of hematopoietic progenitor cells or osteoclast progenitor cells. | 2013-08-08 |
| 20130202613 | PHARMACOLOGICAL VITREOLYSIS - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 2013-08-08 |
| 20130202614 | AUTOTAXIN PATHWAY MODULATION AND USES THEREOF - Disclosed are methods for preventing, treating, or reducing symptoms of a disorder involving the autotaxin (ATX) pathway. In one embodiment, the method features administering to a mammal a sufficient amount of an autotaxin (ATX) or lysophosphatidic acid (LPA) signaling inhibitor, to prevent, treat or reduce symptoms of an inflammatory disorder, autoimmune disorder, fibrosis or malignancy of the lung. Further disclosed are methods for diagnosing an autotaxin-related disorder as well as kits for performing the methods of the invention. | 2013-08-08 |
| 20130202615 | ANTI-VEGF ANTIBODIES AND USES THEREOF - Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer. | 2013-08-08 |
| 20130202616 | COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST BACTERIA EXPRESSING A CARBAPENEMASE - The present invention provides vaccine and pharmaceutical compositions for treating or preventing bacterial inventions. The vaccine compositions of the invention include a carbapenemase such as a serine carbapenemase, a metallo-β-lactamase or an immunogenic fragment thereof. The pharmaceutical compositions include an anti-carbapenemase antibody or fragment thereof. Also provided are methods for treating and preventing a bacterial infection using the vaccine and pharmaceutical compositions of the invention. The invention further provides antibody conjugates that include an antibody or fragment thereof conjugated to a siderophore or an analog thereof. | 2013-08-08 |
| 20130202617 | HEMORRHAGIC FELINE CALICIVIRUS, CALICIVIRUS AND METHOD FOR PREVENTING CALICIVIRUS INFECTION OR DISEASE - The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen. | 2013-08-08 |
| 20130202618 | ANTIBODIES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED INFECTION AND DISEASE - Provided herein are reagents, compositions, and therapies with which to treat | 2013-08-08 |
| 20130202619 | METHODS AND MATERIALS FOR REDUCING LIVER FIBROSIS - This document relates to methods and materials for treating diseases or disorders that are caused by or associated with lumican deposition (e.g., liver fibrosis). For example, methods and materials for reducing liver fibrosis by reducing lumican expression or activity within a mammal (e.g., a human) are provided. | 2013-08-08 |
| 20130202620 | HIGH CONCENTRATION ANTIBODY FORMULATIONS - Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use. | 2013-08-08 |
| 20130202621 | Antibodies Directed To Alpha V Beta 6 And Uses Thereof - Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed. | 2013-08-08 |
| 20130202622 | METHOD FOR THE TREATMENT OF OBESITY - The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes. | 2013-08-08 |
| 20130202623 | PD-1 MODULATION AND USES THEREOF FOR MODULATING HIV REPLICATION - Methods, uses, compositions and kits for modulating HIV replication based on PD-1 modulation are disclosed. Methods, uses, compositions and kits useful for the elimination of latent HIV reservoirs based on PD-1 inhibition are also disclosed. Methods and kits useful for identifying agents useful for modulating HIV replication are also disclosed. | 2013-08-08 |
